Hormonal
Tirzepatide is associated with a significantly increased risk of composite gallbladder or biliary diseases (including cholelithiasis, cholecystitis, and other gallbladder disorders) compared to placebo or basal insulin, but not compared to GLP-1 RAs.
Tirzepatide increases the risk of gallbladder or biliary issues (like gallstones or inflammation) compared to placebos or insulin. However, this risk appears similar to other GLP-1 medications. Be aware of symptoms like abdominal pain and report them to your doctor promptly, as early detection is key.
For gallbladder or biliary disease, the composite of gallbladder or biliary disease was significantly associated with tirzepatide compared with placebo or basal insulin (RR 1.97, [95% CI] 1.14 to 3.42; I2 = 0.0%, p = 0.558)... Compared with GLP1-RA, our analysis did not find a significant association between tirzepatide and the risk of... the composite of gallbladder or biliary diseases
Why this rating
Meta-analysis of 9 RCTs; significant finding with low heterogeneity (I2=0%), though the composite outcome aggregates distinct pathologies.
Source
Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis
Qingyue Zeng et al. · Frontiers in Endocrinology · 2023
DOI 10.3389/fendo.2023.1214334
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →